Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus

BACKGROUND: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifyin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Kota, Shiraki, Katsuhisa, Yoshiyasu, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662943/
https://www.ncbi.nlm.nih.gov/pubmed/26386566
http://dx.doi.org/10.1007/s40268-015-0106-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662943/
https://www.ncbi.nlm.nih.gov/pubmed/26386566
http://dx.doi.org/10.1007/s40268-015-0106-8

Ejemplares similares